var data={"title":"Transjugular intrahepatic portosystemic shunts: Indications and contraindications","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Transjugular intrahepatic portosystemic shunts: Indications and contraindications</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/contributors\" class=\"contributor contributor_credentials\">Arun J Sanyal, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/contributors\" class=\"contributor contributor_credentials\">Jasmohan S Bajaj, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/contributors\" class=\"contributor contributor_credentials\">Bruce A Runyon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/contributors\" class=\"contributor contributor_credentials\">Kristen M Robson, MD, MBA, FACG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 07, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Transjugular intrahepatic portosystemic shunts (TIPS) involve creation of a low-resistance channel between the hepatic vein and the intrahepatic portion of the portal vein (usually the right branch) using angiographic techniques (<a href=\"image.htm?imageKey=GAST%2F72311\" class=\"graphic graphic_figure graphicRef72311 \">figure 1</a> and <a href=\"image.htm?imageKey=RADIOL%2F93243\" class=\"graphic graphic_diagnosticimage graphicRef93243 \">image 1</a>). The tract is kept patent by deployment of an expandable metal stent across it, thereby allowing blood to return to the systemic circulation. The ability of TIPS to function like a surgical side-to-side portacaval shunt without requiring general anesthesia and major surgery led to its rapid acceptance into clinical practice [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/1\" class=\"abstract_t\">1</a>]. However, the expanding use of TIPS has also led to its misuse in some instances.</p><p>This topic will review the indications for TIPS other than variceal bleeding and ascites. It will also review contraindications to TIPS placement and conditions for which TIPS should not be used. The use of TIPS for variceal bleeding and ascites, and the complications associated with this procedure are discussed separately. (See <a href=\"topic.htm?path=role-of-transjugular-intrahepatic-portosystemic-shunts-in-the-treatment-of-variceal-bleeding\" class=\"medical medical_review\">&quot;Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding&quot;</a> and <a href=\"topic.htm?path=ascites-in-adults-with-cirrhosis-diuretic-resistant-ascites#H10\" class=\"medical medical_review\">&quot;Ascites in adults with cirrhosis: Diuretic-resistant ascites&quot;, section on 'Transjugular intrahepatic portosystemic stent-shunt'</a> and <a href=\"topic.htm?path=transjugular-intrahepatic-portosystemic-shunts-complications\" class=\"medical medical_review\">&quot;Transjugular intrahepatic portosystemic shunts: Complications&quot;</a>.)</p><p>A guideline issued by the American Association for the Study of Liver Diseases (AASLD; updated in 2009) is also available [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/2\" class=\"abstract_t\">2</a>]. The AASLD guideline can be accessed through the AASLD <a href=\"http://www.aasld.org/&amp;token=TCZoDJKkgSsgDea9026wfDr9mgHSHgukHC84+b7Zi+A=&amp;TOPIC_ID=1262\" target=\"_blank\" class=\"external\">website</a>.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">VARICEAL BLEEDING AND ASCITES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TIPS has primarily been used to treat the major consequences of portal hypertension (ie, variceal hemorrhage and ascites) (<a href=\"image.htm?imageKey=GAST%2F75996\" class=\"graphic graphic_table graphicRef75996 \">table 1</a>). These topics are discussed in detail elsewhere. (See <a href=\"topic.htm?path=role-of-transjugular-intrahepatic-portosystemic-shunts-in-the-treatment-of-variceal-bleeding\" class=\"medical medical_review\">&quot;Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding&quot;</a> and <a href=\"topic.htm?path=ascites-in-adults-with-cirrhosis-diuretic-resistant-ascites\" class=\"medical medical_review\">&quot;Ascites in adults with cirrhosis: Diuretic-resistant ascites&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">HEPATORENAL SYNDROME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>When used in patients with refractory ascites, insertion of TIPS may lead to a delayed improvement in renal function [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/3,4\" class=\"abstract_t\">3,4</a>]. In one study, the average plasma creatinine concentration was 1.5 <span class=\"nowrap\">mg/dL</span> (132 <span class=\"nowrap\">micromol/L)</span> at baseline, was unchanged at one week, and fell to 0.9 <span class=\"nowrap\">mg/dL</span> (80 <span class=\"nowrap\">micromol/L)</span> by six months [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/4\" class=\"abstract_t\">4</a>].</p><p>There is much less information on the use of TIPS in patients who fulfill criteria for the hepatorenal syndrome (see <a href=\"topic.htm?path=hepatorenal-syndrome\" class=\"medical medical_review\">&quot;Hepatorenal syndrome&quot;</a>). One report described 16 such patients, six of whom had severe hepatorenal syndrome (defined as a plasma creatinine concentration &ge;2.5 <span class=\"nowrap\">mg/dL</span> [220 <span class=\"nowrap\">micromol/L]</span> or a creatinine clearance below 20 <span class=\"nowrap\">mL/min)</span> [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/5\" class=\"abstract_t\">5</a>]. Within two weeks, there was an approximate doubling of the creatinine clearance with a proportionate reduction in the plasma creatinine concentration and an increase in urinary sodium excretion. Modest further improvement in creatinine clearance occurred over the ensuing six to eight weeks. Only three patients were nonresponders; all three died within six weeks after TIPS.</p><p>Another series evaluated seven patients with cirrhosis and hepatorenal syndrome (defined as a doubling of the plasma creatinine concentration to more than 2.5 <span class=\"nowrap\">mg/dL</span> [221 <span class=\"nowrap\">micromol/L]</span> or a 50 percent reduction in creatinine clearance to below 20 <span class=\"nowrap\">mL/min</span> in less than two weeks despite volume expansion) [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/6\" class=\"abstract_t\">6</a>]. Insertion of TIPS was associated with a gradual improvement in glomerular filtration rate (9 to 27 <span class=\"nowrap\">mL/min),</span> reductions in the BUN and plasma creatinine concentration, and a reduction in the activity of the renin-angiotensin and sympathetic nervous systems in six, all of which suggest an improvement in systemic hemodynamics (see <a href=\"topic.htm?path=pathogenesis-of-ascites-in-patients-with-cirrhosis\" class=\"medical medical_review\">&quot;Pathogenesis of ascites in patients with cirrhosis&quot;</a>). The average survival following TIPS placement was approximately five months, which is longer than the expected survival of such patients.</p><p>These results suggest that, in selected patients with hepatorenal syndrome, TIPS may provide short-term benefit. However, given the risks associated with this procedure (particularly the high incidence of encephalopathy), it should be considered only as a last resort in patients who are not candidates for or are awaiting liver transplantation. The American Association for the Study of Liver Diseases does not recommend TIPS for the treatment of hepatorenal syndrome, especially type 1 hepatorenal syndrome, pending the publication of controlled trials [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">MISCELLANEOUS USES OF TIPS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TIPS has been used in a variety of other conditions. In most cases, only small series have been published and the indications for TIPS remain unclear.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Budd-Chiari syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of Budd-Chiari syndrome depends on its cause and clinical presentation. The role of TIPS is described separately. (See <a href=\"topic.htm?path=budd-chiari-syndrome-management#H330914071\" class=\"medical medical_review\">&quot;Budd-Chiari syndrome: Management&quot;, section on 'Transjugular intrahepatic portosystemic shunt'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Hepatic sinusoidal obstruction syndrome (veno-occlusive disease)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hepatic sinusoidal obstruction syndrome (SOS) is an important complication of bone marrow transplantation. The pathophysiology of this condition is related to increased sinusoidal pressures from occlusion of microscopic hepatic venules and central veins in the hepatic lobules. (See <a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation&quot;</a>.)</p><p>Insertion of TIPS has been performed in small numbers of patients with SOS, some of whom had regression of the hepatic and renal symptoms [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/8\" class=\"abstract_t\">8</a>]. Patients with milder disease appear to be more likely to respond, but long-term survival appears to be uncommon [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/8\" class=\"abstract_t\">8</a>]. Furthermore, it is unclear whether these patents would have improved spontaneously. At present, the use of TIPS for SOS should be considered experimental and individualized until more data are available [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Hepatic hydrothorax</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The development of a persistent symptomatic hydrothorax in a patient with cirrhosis is an ominous sign and warrants urgent liver transplantation. However, treatment is required as a bridge to transplantation. The therapeutic options include repeated thoracenteses, pleurodesis, or a peritoneovenous shunt in patients with significant ascites. (See <a href=\"topic.htm?path=management-of-refractory-nonmalignant-pleural-effusions\" class=\"medical medical_review\">&quot;Management of refractory nonmalignant pleural effusions&quot;</a>.)</p><p>Several groups have reported a beneficial effect of TIPS in patients with hepatic hydrothorax. Unfortunately, very few of the studies described the rigor with which the refractoriness of the hydrothorax to medical therapy was determined. Mortality is high in patients with a Child-Pugh score of 12 or higher [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/9\" class=\"abstract_t\">9</a>]. We consider liver transplantation to be the definitive treatment for refractory cirrhotic hydrothorax. TIPS may be used with caution in selected patients with a Child-Pugh score less than 10 (<a href=\"topic.htm?path=calculator-child-pugh-classification-for-severity-of-liver-disease\" class=\"calc calc_professional\">calculator 1</a> and <a href=\"topic.htm?path=calculator-child-pugh-classification-for-severity-of-liver-disease-si-units\" class=\"calc calc_professional\">calculator 2</a>) (<a href=\"image.htm?imageKey=GAST%2F78401\" class=\"graphic graphic_table graphicRef78401 \">table 2</a>). (See <a href=\"topic.htm?path=hepatic-hydrothorax\" class=\"medical medical_review\">&quot;Hepatic hydrothorax&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Portal hypertensive gastropathy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Portal hypertensive gastropathy is characterized by venous and capillary ectasia in gastrointestinal mucosa and submucosa with minimal associated inflammation (<a href=\"image.htm?imageKey=GAST%2F75725\" class=\"graphic graphic_picture graphicRef75725 \">picture 1</a>) (see <a href=\"topic.htm?path=portal-hypertensive-gastropathy\" class=\"medical medical_review\">&quot;Portal hypertensive gastropathy&quot;</a>). It is principally described in the stomach, but may also exist in the colon and other parts of the gastrointestinal tract.</p><p>Portal hypertensive gastropathy is a common finding in cirrhosis, but only occasionally causes recurrent bleeding requiring frequent transfusions. The treatment options include beta blockers, portacaval shunt surgery, and TIPS. Because TIPS is invasive and associated with significant morbidity, it is generally reserved for patients who fail less invasive treatments (eg, a nonselective beta blocker). (See <a href=\"topic.htm?path=portal-hypertensive-gastropathy#H325154496\" class=\"medical medical_review\">&quot;Portal hypertensive gastropathy&quot;, section on 'Refractory bleeding'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Prior to abdominal surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with portal hypertension have an increased risk of bleeding during intraabdominal surgery. Case reports have suggested that the risk might be reduced by preoperative placement of a TIPS [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/10\" class=\"abstract_t\">10</a>]. However, other studies have not found a decrease in the need for transfusion, ICU stay, or mortality with preoperative decompression of the portal vein with TIPS in patients with cirrhosis [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/11-13\" class=\"abstract_t\">11-13</a>]. Based upon current evidence, TIPS cannot be routinely recommended prior to nonhepatic abdominal surgery in those with cirrhosis.</p><p class=\"headingAnchor\" id=\"H141506961\"><span class=\"h1\">CONTRAINDICATIONS TO TIPS PLACEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are several absolute and relative contraindications to TIPS placement [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/7\" class=\"abstract_t\">7</a>].</p><p>Absolute contraindications include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Heart failure</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe tricuspid regurgitation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe pulmonary hypertension (mean pulmonary pressure &gt;45 mmHg)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple hepatic cysts</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Uncontrolled systemic infection or sepsis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unrelieved biliary obstruction</p><p/><p>A cardiac evaluation should be performed prior to TIPS placement in patients with signs, symptoms, or a history of heart failure, tricuspid regurgitation, cardiomyopathy, or pulmonary hypertension. The evaluation may include an echocardiogram, cardiology consultation, and in some cases, an atrial fluid challenge. In patients who do not have a cardiac history, the appropriate evaluation is less clear. We agree with a 2005 guideline from the American Association for the Study of Liver Diseases that does not recommend routine echocardiograms prior to TIPS placement [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/7\" class=\"abstract_t\">7</a>]. However, there are those who recommend routine echocardiography because pulmonary hypertension is seen in up to 16 percent of patients being referred for liver transplantation [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Relative contraindications include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatoma, especially if central</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Obstruction of all hepatic veins</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Portal vein thrombosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Severe coagulopathy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thrombocytopenia <span class=\"nowrap\">(&lt;20,000/mm<sup>3</sup>)</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moderate pulmonary hypertension</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">CONDITIONS FOR WHICH TIPS SHOULD NOT BE USED</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The widespread availability of TIPS has led to its use in the context of virtually all aspects of cirrhosis. Needless to say, many such indications are not warranted, particularly when one considers the frequent complications associated with this procedure. (See <a href=\"topic.htm?path=transjugular-intrahepatic-portosystemic-shunts-complications\" class=\"medical medical_review\">&quot;Transjugular intrahepatic portosystemic shunts: Complications&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Primary prophylaxis of variceal hemorrhage</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Only one-third of patients with esophageal varices will experience variceal hemorrhage. Pharmacologic treatment with nonselective beta blockers achieves a decrease in bleeding frequency with relatively little morbidity (see <a href=\"topic.htm?path=primary-and-pre-primary-prophylaxis-against-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">&quot;Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis&quot;</a>). By comparison, TIPS is an expensive, invasive procedure with significant morbidity and mortality [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/15\" class=\"abstract_t\">15</a>]. It also requires close follow-up due to the high incidence of shunt stenosis, and recurrent portal hypertension.</p><p>Thus, TIPS is not indicated for the primary prophylaxis of variceal hemorrhage. Similarly, TIPS does not affect the outcome of liver transplantation [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/11,13,16\" class=\"abstract_t\">11,13,16</a>] and is not indicated for preoperative portal decompression prior to transplantation. </p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Prehepatic portal hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prehepatic portal hypertension results most commonly from portal vein thrombosis or tumors at the porta hepatis. Several anecdotal reports have documented that TIPS can be placed into a collateral vein, or following dilation of a thrombosed portal vein [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/17,18\" class=\"abstract_t\">17,18</a>]. However, since the low-resistance tract is being created downstream from the site of obstruction, it is unlikely to adequately decompress the portal system. There currently are not enough data to support the use of TIPS in such patients. </p><p>There have been cases of acute portal vein thrombosis effectively treated by placement of a TIPS followed by aggressive thrombolysis or anticoagulation [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/19,20\" class=\"abstract_t\">19,20</a>]. However, it has been our experience that this is associated with occasional morbidity due to bleeding, which can be severe.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Correction of hypersplenism and thrombocytopenia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thrombocytopenia in patients with cirrhosis has primarily been ascribed to splenic engorgement and sequestration. However, other factors such as a low thrombopoietin levels may also contribute [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/21\" class=\"abstract_t\">21</a>] (see <a href=\"topic.htm?path=biology-and-physiology-of-thrombopoietin\" class=\"medical medical_review\">&quot;Biology and physiology of thrombopoietin&quot;</a>). In addition to these chronic factors, the consumption of platelets and dilution by blood and plasma transfusions during episodes of bleeding can cause an acute fall in the platelet count.</p><p>Several small series have noted an improvement in the platelet count within a few days of TIPS placement [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/22-24\" class=\"abstract_t\">22-24</a>]. However, a problem with these studies is that the baseline values were obtained during active bleeding; thus, the early increase in platelet counts may have reflected a return to baseline values in such patients. In a systematic prospective study of 60 subjects in whom &quot;true&quot; baseline data were obtained, the mean platelet counts remained unchanged after TIPS [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/25\" class=\"abstract_t\">25</a>]. Although a small number of patients did experience a long-lasting increase in platelet counts, there were no clinical markers that could identify these subjects. Similar findings have been reported in other series [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/26\" class=\"abstract_t\">26</a>]. These data corroborate those obtained after surgical portal decompression [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/27,28\" class=\"abstract_t\">27,28</a>]. Thus, TIPS should not be performed simply to increase platelet counts in cirrhotics with thrombocytopenia.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Pulmonary hypertension and hepatopulmonary syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Cirrhosis is sometimes complicated by the development of severe pulmonary hypertension [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/29\" class=\"abstract_t\">29</a>]. The pathogenesis of this syndrome is obscure. Many patients are diagnosed only during evaluation for liver transplant, and the true incidence in unknown. The presence of severe pulmonary hypertension is associated with a poor outcome after liver transplantation.</p><p>The hepatopulmonary syndrome is a separate condition that is characterized by arteriovenous shunting within the pulmonary bed, producing a right-to-left shunt and systemic hypoxemia. (See <a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis&quot;</a>.)</p><p>The effect of TIPS on the pulmonary circulation is complex, and depends upon the dynamic interaction of the changes in venous return, effective circulating volume, systemic vascular resistance, and myocardial reserve. Following TIPS, there is an immediate increase in venous return to the heart [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/30\" class=\"abstract_t\">30</a>]. Simultaneously, systemic vascular resistance decreases, further worsening the hyperdynamic circulatory state already present [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/30-32\" class=\"abstract_t\">30-32</a>]. Cardiac output increases in response to these changes. When the heart's ability to handle this &quot;volume-overload&quot; is exceeded, pulmonary venous pressures rise, with increasing <span class=\"nowrap\">V/Q</span> mismatch, hypoxia and pulmonary vasoconstriction; pulmonary edema may ensue.</p><p>The varying outcome of patients with cirrhotic pulmonary hypertension and hepatopulmonary syndrome after TIPS is due to differences in the interactions between these variables [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/7,33,34\" class=\"abstract_t\">7,33,34</a>]. TIPS should not be performed for these conditions. The outcome is not predictable, and TIPS may actually be detrimental. (See <a href=\"topic.htm?path=portopulmonary-hypertension\" class=\"medical medical_review\">&quot;Portopulmonary hypertension&quot;</a> and <a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Portal hypertension associated with polycystic liver disease or Caroli disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both polycystic liver disease and Caroli disease (a variant of choledochal cyst disease characterized by multiple cystic dilations of the intrahepatic biliary ducts) may be complicated by portal hypertension and variceal hemorrhage. The creation of an intrahepatic tract may involve traversal of a cyst, which is associated with a high risk of severe hemorrhage. TIPS is therefore best avoided in such patients [<a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/35\" class=\"abstract_t\">35</a>]. (See <a href=\"topic.htm?path=extrarenal-manifestations-of-autosomal-dominant-polycystic-kidney-disease\" class=\"medical medical_review\">&quot;Extrarenal manifestations of autosomal dominant polycystic kidney disease&quot;</a> and <a href=\"topic.htm?path=caroli-disease\" class=\"medical medical_review\">&quot;Caroli disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3070983116\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-portal-hypertension-and-ascites\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Portal hypertension and ascites&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H38798044\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Transjugular intrahepatic portosystemic shunts (TIPS) have primarily been used to treat the major consequences of portal hypertension (ie, variceal hemorrhage and ascites) (<a href=\"image.htm?imageKey=GAST%2F75996\" class=\"graphic graphic_table graphicRef75996 \">table 1</a>). (See <a href=\"topic.htm?path=role-of-transjugular-intrahepatic-portosystemic-shunts-in-the-treatment-of-variceal-bleeding\" class=\"medical medical_review\">&quot;Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding&quot;</a> and <a href=\"topic.htm?path=ascites-in-adults-with-cirrhosis-diuretic-resistant-ascites\" class=\"medical medical_review\">&quot;Ascites in adults with cirrhosis: Diuretic-resistant ascites&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is less clear if TIPS is helpful for:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hepatorenal syndrome (see <a href=\"#H3\" class=\"local\">'Hepatorenal syndrome'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Budd-Chiari syndrome (see <a href=\"topic.htm?path=budd-chiari-syndrome-management#H330914071\" class=\"medical medical_review\">&quot;Budd-Chiari syndrome: Management&quot;, section on 'Transjugular intrahepatic portosystemic shunt'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hepatic sinusoidal obstruction syndrome (see <a href=\"#H6\" class=\"local\">'Hepatic sinusoidal obstruction syndrome (veno-occlusive disease)'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hepatic hydrothorax (see <a href=\"topic.htm?path=hepatic-hydrothorax#H9\" class=\"medical medical_review\">&quot;Hepatic hydrothorax&quot;, section on 'Transjugular intrahepatic portosystemic shunt (TIPS)'</a>) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Portal hypertensive gastropathy (see <a href=\"#H8\" class=\"local\">'Portal hypertensive gastropathy'</a> above) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Prior to abdominal surgery (see <a href=\"#H9\" class=\"local\">'Prior to abdominal surgery'</a> above) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>TIPS should <strong>not </strong>be used for:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Primary prophylaxis of variceal hemorrhage (see <a href=\"#H11\" class=\"local\">'Primary prophylaxis of variceal hemorrhage'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Prehepatic portal hypertension (see <a href=\"#H12\" class=\"local\">'Prehepatic portal hypertension'</a> above) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Correction of hypersplenism and thrombocytopenia (see <a href=\"#H13\" class=\"local\">'Correction of hypersplenism and thrombocytopenia'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Pulmonary hypertension and hepatopulmonary syndrome (see <a href=\"#H14\" class=\"local\">'Pulmonary hypertension and hepatopulmonary syndrome'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Portal hypertension associated with polycystic liver disease or Caroli disease (see <a href=\"#H15\" class=\"local\">'Portal hypertension associated with polycystic liver disease or Caroli disease'</a> above)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/1\" class=\"nounderline abstract_t\">Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003; 124:1700.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/2\" class=\"nounderline abstract_t\">Boyer TD, Haskal ZJ, American Association for the Study of Liver Diseases. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology 2010; 51:306.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/3\" class=\"nounderline abstract_t\">Somberg KA, Lake JR, Tomlanovich SJ, et al. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995; 21:709.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/4\" class=\"nounderline abstract_t\">Ochs A, R&ouml;ssle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332:1192.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/5\" class=\"nounderline abstract_t\">Brensing KA, Textor J, Strunk H, et al. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997; 349:697.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/6\" class=\"nounderline abstract_t\">Guevara M, Gin&egrave;s P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28:416.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/7\" class=\"nounderline abstract_t\">Boyer TD, Haskal ZJ, American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41:386.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/8\" class=\"nounderline abstract_t\">Fried MW, Connaghan DG, Sharma S, et al. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24:588.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/9\" class=\"nounderline abstract_t\">Chalasani N, Gitlin N. TIPS for patients with refractory hepatic hydrothorax: what is the take-home message? Am J Gastroenterol 1997; 92:2129.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/10\" class=\"nounderline abstract_t\">Azoulay D, Buabse F, Damiano I, et al. Neoadjuvant transjugular intrahepatic portosystemic shunt: a solution for extrahepatic abdominal operation in cirrhotic patients with severe portal hypertension. J Am Coll Surg 2001; 193:46.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/11\" class=\"nounderline abstract_t\">Somberg KA, Lombardero MS, Lawlor SM, et al. A controlled analysis of the transjugular intrahepatic portosystemic shunt in liver transplant recipients. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Liver Transplantation Database. Transplantation 1997; 63:1074.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/12\" class=\"nounderline abstract_t\">Vinet E, Perreault P, Bouchard L, et al. Transjugular intrahepatic portosystemic shunt before abdominal surgery in cirrhotic patients: a retrospective, comparative study. Can J Gastroenterol 2006; 20:401.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/13\" class=\"nounderline abstract_t\">Millis JM, Martin P, Gomes A, et al. Transjugular intrahepatic portosystemic shunts: impact on liver transplantation. Liver Transpl Surg 1995; 1:229.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/14\" class=\"nounderline abstract_t\">Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/15\" class=\"nounderline abstract_t\">Freedman AM, Sanyal AJ, Tisnado J, et al. Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics 1993; 13:1185.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/16\" class=\"nounderline abstract_t\">Abouljoud MS, Levy MF, Rees CR, et al. A comparison of treatment with transjugular intrahepatic portosystemic shunt or distal splenorenal shunt in the management of variceal bleeding prior to liver transplantation. Transplantation 1995; 59:226.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/17\" class=\"nounderline abstract_t\">H&auml;nig V, Stenzel G, R&ouml;ssle M. [Acute portal vein thrombosis in liver cirrhosis: successful recanalization with the use of a portosystemic shunt (TIPS)]. Rofo 1996; 165:403.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/18\" class=\"nounderline abstract_t\">Radosevich PM, Ring EJ, LaBerge JM, et al. Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion. Radiology 1993; 186:523.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/19\" class=\"nounderline abstract_t\">Ferro C, Rossi UG, Bovio G, et al. Transjugular intrahepatic portosystemic shunt, mechanical aspiration thrombectomy, and direct thrombolysis in the treatment of acute portal and superior mesenteric vein thrombosis. Cardiovasc Intervent Radiol 2007; 30:1070.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/20\" class=\"nounderline abstract_t\">Kori I, Bar-Zohar D, Carmiel-Haggai M, et al. Budd-Chiari syndrome and acute portal vein thrombosis: management by a transjugular intrahepatic portosystemic shunt (TIPS) and portal vein interventions via a TIPS. J Gastrointest Surg 2006; 10:417.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/21\" class=\"nounderline abstract_t\">Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997; 27:127.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/22\" class=\"nounderline abstract_t\">Alvarez OA, Lopera GA, Patel V, et al. Improvement of thrombocytopenia due to hypersplenism after transjugular intrahepatic portosystemic shunt placement in cirrhotic patients. Am J Gastroenterol 1996; 91:134.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/23\" class=\"nounderline abstract_t\">Lawrence SP, Lezotte DC, Durham JD, et al. Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS). A retrospective analysis. Dig Dis Sci 1995; 40:1575.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/24\" class=\"nounderline abstract_t\">Pursnani KG, Sillin LF, Kaplan DS. Effect of transjugular intrahepatic portosystemic shunt on secondary hypersplenism. Am J Surg 1997; 173:169.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/25\" class=\"nounderline abstract_t\">Sanyal AJ, Freedman AM, Purdum PP, et al. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 1996; 23:32.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/26\" class=\"nounderline abstract_t\">Jabbour N, Zajko A, Orons P, et al. Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci 1998; 43:2459.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/27\" class=\"nounderline abstract_t\">Mutchnick MG, Lerner E, Conn HO. Effect of portacaval anastomosis on hypersplenism. Dig Dis Sci 1980; 25:929.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/28\" class=\"nounderline abstract_t\">Felix WR Jr, Myerson RM, Sigel B, et al. The effect of portacaval shunt on hypersplenism. Surg Gynecol Obstet 1974; 139:899.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/29\" class=\"nounderline abstract_t\">Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100:520.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/30\" class=\"nounderline abstract_t\">Azoulay D, Castaing D, Dennison A, et al. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study. Hepatology 1994; 19:129.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/31\" class=\"nounderline abstract_t\">Colombato LA, Spahr L, Martinet JP, et al. Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients. Gut 1996; 39:600.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/32\" class=\"nounderline abstract_t\">Rodr&iacute;guez-Laiz JM, Ba&ntilde;ares R, Echenagusia A, et al. Effects of transjugular intrahepatic portasystemic shunt (TIPS) on splanchnic and systemic hemodynamics, and hepatic function in patients with portal hypertension. Preliminary results. Dig Dis Sci 1995; 40:2121.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/33\" class=\"nounderline abstract_t\">van der Heijde RM, Lam&eacute;ris JS, van den Berg B, et al. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt (TIPS). Eur Respir J 1996; 9:1562.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/34\" class=\"nounderline abstract_t\">Willoughby PH, Beers RA, Murphy KD. Pulmonary edema after transjugular intrahepatic portosystemic shunt. Anesth Analg 1996; 82:895.</a></li><li><a href=\"https://www.uptodate.com/contents/transjugular-intrahepatic-portosystemic-shunts-indications-and-contraindications/abstract/35\" class=\"nounderline abstract_t\">Shiffman ML, Jeffers L, Hoofnagle JH, Tralka TS. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. Hepatology 1995; 22:1591.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1262 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H38798044\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">VARICEAL BLEEDING AND ASCITES</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">HEPATORENAL SYNDROME</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">MISCELLANEOUS USES OF TIPS</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Budd-Chiari syndrome</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Hepatic sinusoidal obstruction syndrome (veno-occlusive disease)</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Hepatic hydrothorax</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Portal hypertensive gastropathy</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Prior to abdominal surgery</a></li></ul></li><li><a href=\"#H141506961\" id=\"outline-link-H141506961\">CONTRAINDICATIONS TO TIPS PLACEMENT</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">CONDITIONS FOR WHICH TIPS SHOULD NOT BE USED</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Primary prophylaxis of variceal hemorrhage</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Prehepatic portal hypertension</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Correction of hypersplenism and thrombocytopenia</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Pulmonary hypertension and hepatopulmonary syndrome</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Portal hypertension associated with polycystic liver disease or Caroli disease</a></li></ul></li><li><a href=\"#H3070983116\" id=\"outline-link-H3070983116\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H38798044\" id=\"outline-link-H38798044\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/1262|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=RADIOL/93243\" class=\"graphic graphic_diagnosticimage\">- TIPS placement</a></li></ul></li><li><div id=\"GAST/1262|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/72311\" class=\"graphic graphic_figure\">- Transjugular intrahepatic portosystemic shunt</a></li></ul></li><li><div id=\"GAST/1262|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/75725\" class=\"graphic graphic_picture\">- Portal hypertensive gastropathy</a></li></ul></li><li><div id=\"GAST/1262|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/75996\" class=\"graphic graphic_table\">- Indications for TIPS</a></li><li><a href=\"image.htm?imageKey=GAST/78401\" class=\"graphic graphic_table\">- Child-Pugh classification</a></li></ul></li></ul></div></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-child-pugh-classification-for-severity-of-liver-disease\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Child Pugh classification for severity of liver disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-child-pugh-classification-for-severity-of-liver-disease-si-units\" title=\"calculator 2\" class=\"calc calc_professional\">Calculator: Child Pugh classification for severity of liver disease (SI units)</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=ascites-in-adults-with-cirrhosis-diuretic-resistant-ascites\" class=\"medical medical_review\">Ascites in adults with cirrhosis: Diuretic-resistant ascites</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=biology-and-physiology-of-thrombopoietin\" class=\"medical medical_review\">Biology and physiology of thrombopoietin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=budd-chiari-syndrome-management\" class=\"medical medical_review\">Budd-Chiari syndrome: Management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=caroli-disease\" class=\"medical medical_review\">Caroli disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extrarenal-manifestations-of-autosomal-dominant-polycystic-kidney-disease\" class=\"medical medical_review\">Extrarenal manifestations of autosomal dominant polycystic kidney disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatic-hydrothorax\" class=\"medical medical_review\">Hepatic hydrothorax</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatopulmonary-syndrome-in-adults-prevalence-causes-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatorenal-syndrome\" class=\"medical medical_review\">Hepatorenal syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-refractory-nonmalignant-pleural-effusions\" class=\"medical medical_review\">Management of refractory nonmalignant pleural effusions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-ascites-in-patients-with-cirrhosis\" class=\"medical medical_review\">Pathogenesis of ascites in patients with cirrhosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=portal-hypertensive-gastropathy\" class=\"medical medical_review\">Portal hypertensive gastropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=portopulmonary-hypertension\" class=\"medical medical_review\">Portopulmonary hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-and-pre-primary-prophylaxis-against-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-transjugular-intrahepatic-portosystemic-shunts-in-the-treatment-of-variceal-bleeding\" class=\"medical medical_review\">Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-portal-hypertension-and-ascites\" class=\"medical medical_society_guidelines\">Society guideline links: Portal hypertension and ascites</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=transjugular-intrahepatic-portosystemic-shunts-complications\" class=\"medical medical_review\">Transjugular intrahepatic portosystemic shunts: Complications</a></li></ul></div></div>","javascript":null}